Overview

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

Status:
Recruiting

Trial end date:
2023-08-15

Target enrollment:

Participant gender:

Summary

An open, multicenter phase II clinical study to evaluate safety and efficacy of HLX208 (BRAF V600E inhibitor) combined with cetuximab for metastatic colorectal cancer (mCRC) with BRAF V600E Mutation after first-line treatment

Phase:

Phase 2

Details

Lead Sponsor:

Shanghai Henlius Biotech

Treatments:

Cetuximab